Thrombin Induces Angiotensin II-Mediated Senescence in Atrial Endothelial Cells: Impact on Pro-Remodeling Patterns.

angiotensin II atrial fibrillation endothelium remodeling senescence thrombin

Journal

Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588

Informations de publication

Date de publication:
01 Oct 2019
Historique:
received: 29 08 2019
revised: 16 09 2019
accepted: 25 09 2019
entrez: 5 10 2019
pubmed: 5 10 2019
medline: 5 10 2019
Statut: epublish

Résumé

Besides its well-known functions in hemostasis, thrombin plays a role in various non-hemostatic biological and pathophysiologic processes. We examined the potential of thrombin to promote premature atrial endothelial cells (ECs) senescence. Primary ECs were isolated from porcine atrial tissue. Endothelial senescence was assessed by measuring beta-galactosidase (SA-β-gal) activity using flow cytometry, oxidative stress using the redox-sensitive probe dihydroethidium, protein level by Western blot, and matrix metalloproteinases (MMPs) activity using zymography. Atrial endothelial senescence was induced by thrombin at clinically relevant concentrations. Thrombin induced the up-regulation of p53, a key regulator in cellular senescence and of p21 and p16, two cyclin-dependent kinase inhibitors. Nicotinamide adenine dinucleotide phosphate NADPH oxidase, cyclooxygenases and the mitochondrial respiration complex contributed to oxidative stress and senescence. Enhanced expression levels of vascular cell adhesion molecule (VCAM)-1, tissue factor, transforming growth factor (TGF)-β and MMP-2 and 9 characterized the senescence-associated secretory phenotype of atrial ECs. In addition, the pro-senescence endothelial response to thrombin was associated with an overexpression of both angiotensin converting enzyme and AT1 receptors and was inhibited by perindoprilat and losartan. Thrombin promotes premature ageing and senescence of atrial ECs and may pave the way to deleterious remodeling of atrial tissue by a local up-regulation of the angiotensin system and by promoting pro-inflammatory, pro-thrombotic, pro-fibrotic and pro-remodeling responses. Hence, targeting thrombin and/or angiotensin systems may efficiently prevent atrial endothelial senescence.

Sections du résumé

BACKGROUND BACKGROUND
Besides its well-known functions in hemostasis, thrombin plays a role in various non-hemostatic biological and pathophysiologic processes. We examined the potential of thrombin to promote premature atrial endothelial cells (ECs) senescence.
METHODS AND RESULTS RESULTS
Primary ECs were isolated from porcine atrial tissue. Endothelial senescence was assessed by measuring beta-galactosidase (SA-β-gal) activity using flow cytometry, oxidative stress using the redox-sensitive probe dihydroethidium, protein level by Western blot, and matrix metalloproteinases (MMPs) activity using zymography. Atrial endothelial senescence was induced by thrombin at clinically relevant concentrations. Thrombin induced the up-regulation of p53, a key regulator in cellular senescence and of p21 and p16, two cyclin-dependent kinase inhibitors. Nicotinamide adenine dinucleotide phosphate NADPH oxidase, cyclooxygenases and the mitochondrial respiration complex contributed to oxidative stress and senescence. Enhanced expression levels of vascular cell adhesion molecule (VCAM)-1, tissue factor, transforming growth factor (TGF)-β and MMP-2 and 9 characterized the senescence-associated secretory phenotype of atrial ECs. In addition, the pro-senescence endothelial response to thrombin was associated with an overexpression of both angiotensin converting enzyme and AT1 receptors and was inhibited by perindoprilat and losartan.
CONCLUSIONS CONCLUSIONS
Thrombin promotes premature ageing and senescence of atrial ECs and may pave the way to deleterious remodeling of atrial tissue by a local up-regulation of the angiotensin system and by promoting pro-inflammatory, pro-thrombotic, pro-fibrotic and pro-remodeling responses. Hence, targeting thrombin and/or angiotensin systems may efficiently prevent atrial endothelial senescence.

Identifiants

pubmed: 31581517
pii: jcm8101570
doi: 10.3390/jcm8101570
pmc: PMC6833093
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

Oncotarget. 2017 Aug 3;8(35):57981-57990
pubmed: 28938531
J Thromb Haemost. 2003 Jul;1(7):1504-14
pubmed: 12871286
Int J Cardiol. 2018 Nov 15;271:219-227
pubmed: 29801760
Int J Cardiol. 2013 Sep 30;168(2):660-9
pubmed: 23623666
J Cardiovasc Electrophysiol. 2016 Oct;27(10):1220-1229
pubmed: 27447370
Cardiovasc Res. 2014 Mar 1;101(3):344-51
pubmed: 24385341
J Vis Exp. 2010 Nov 08;(45):null
pubmed: 21085107
Heart Rhythm. 2016 Jan;13(1):21-7
pubmed: 26231419
J Cardiothorac Surg. 2017 Aug 18;12(1):70
pubmed: 28821262
J Thromb Haemost. 2011 Dec;9(12):2345-52
pubmed: 21972893
Eur J Pharmacol. 2013 Oct 15;718(1-3):114-23
pubmed: 24041930
Cardiovasc Res. 2005 Sep 1;67(4):655-66
pubmed: 15913581
Lancet. 2009 Jan 10;373(9658):155-66
pubmed: 19135613
Circ Res. 2004 Jun 11;94(11):1458-65
pubmed: 15117823
J Cell Mol Med. 2008 Jan-Feb;12(1):189-208
pubmed: 18194448
Cardiovasc Res. 1994 Aug;28(8):1263-8
pubmed: 7954631
Thromb Res. 2017 Jan;149:17-24
pubmed: 27865966
Circulation. 2017 Jan 17;135(3):280-296
pubmed: 27821539
Cancer Sci. 2017 Apr;108(4):563-569
pubmed: 28165648
J Mol Cell Cardiol. 2018 Nov;124:12-25
pubmed: 30273558
Am J Cardiol. 2007 Sep 15;100(6):989-94
pubmed: 17826384
Circulation. 2004 Jan 27;109(3):363-8
pubmed: 14732752
J Thromb Haemost. 2006 Jun;4(6):1296-302
pubmed: 16706974
J Biol Chem. 2010 Dec 31;285(53):41432-42
pubmed: 21041303
Int J Cardiol. 2011 Aug 4;150(3):270-6
pubmed: 20447702
Circ Arrhythm Electrophysiol. 2012 Dec;5(6):1176-83
pubmed: 23118275
Circulation. 1994 May;89(5):2266-72
pubmed: 8181152
Biochem Pharmacol. 1991 Jun 21;42(1):13-6
pubmed: 2069586
Arterioscler Thromb Vasc Biol. 2006 Dec;26(12):2594-604
pubmed: 16990554
J Cell Sci. 2000 Oct;113 ( Pt 20):3613-22
pubmed: 11017877
J Renin Angiotensin Aldosterone Syst. 2009 Dec;10(4):190-4
pubmed: 19617274
JACC Basic Transl Sci. 2016 Jul 13;1(5):328-339
pubmed: 27642643
J Gerontol A Biol Sci Med Sci. 2016 Dec;71(12):1581-1590
pubmed: 26672612
Blood. 2005 Mar 1;105(5):1977-85
pubmed: 15522964
J Biol Chem. 2003 May 9;278(19):17368-78
pubmed: 12606553
Heart Rhythm. 2018 Nov;15(11):1717-1727
pubmed: 29908372
Sci Rep. 2016 Oct 18;6:35580
pubmed: 27752126
Eur Heart J. 2017 Jan 1;38(1):38-50
pubmed: 27071821
Can J Cardiol. 2016 May;32(5):612-23
pubmed: 27040096
J Cardiovasc Pharmacol Ther. 2013 Sep;18(5):460-75
pubmed: 23598708
Oxid Med Cell Longev. 2016;2016:5047954
pubmed: 27313830
J Am Coll Cardiol. 2008 May 6;51(18):1790-3
pubmed: 18452786

Auteurs

Hira Hasan (H)

INSERM UMR1260 Regenerative NanoMedicine, Fédération de Médecine Translationnelle de Strasbourg, Université de Strasbourg, Faculté de Pharmacie, BP 60024 FR-67401 Strasbourg, France.

Sin-Hee Park (SH)

INSERM UMR1260 Regenerative NanoMedicine, Fédération de Médecine Translationnelle de Strasbourg, Université de Strasbourg, Faculté de Pharmacie, BP 60024 FR-67401 Strasbourg, France.

Cyril Auger (C)

INSERM UMR1260 Regenerative NanoMedicine, Fédération de Médecine Translationnelle de Strasbourg, Université de Strasbourg, Faculté de Pharmacie, BP 60024 FR-67401 Strasbourg, France.

Eugenia Belcastro (E)

INSERM UMR1260 Regenerative NanoMedicine, Fédération de Médecine Translationnelle de Strasbourg, Université de Strasbourg, Faculté de Pharmacie, BP 60024 FR-67401 Strasbourg, France.

Kensuke Matsushita (K)

INSERM UMR1260 Regenerative NanoMedicine, Fédération de Médecine Translationnelle de Strasbourg, Université de Strasbourg, Faculté de Pharmacie, BP 60024 FR-67401 Strasbourg, France.

Benjamin Marchandot (B)

Pôle d'Activité Médico-Chirurgicale Cardio-Vasculaire, Nouvel Hôpital Civil, Centre Hospitalier Universitaire, Fédération de Médecine Translationnelle de Strasbourg, Strasbourg, BP 426-67091 France.

Hyun-Ho Lee (HH)

INSERM UMR1260 Regenerative NanoMedicine, Fédération de Médecine Translationnelle de Strasbourg, Université de Strasbourg, Faculté de Pharmacie, BP 60024 FR-67401 Strasbourg, France.

Abdul Wahid Qureshi (AW)

INSERM UMR1260 Regenerative NanoMedicine, Fédération de Médecine Translationnelle de Strasbourg, Université de Strasbourg, Faculté de Pharmacie, BP 60024 FR-67401 Strasbourg, France.

Gilles Kauffenstein (G)

INSERM UMR1260 Regenerative NanoMedicine, Fédération de Médecine Translationnelle de Strasbourg, Université de Strasbourg, Faculté de Pharmacie, BP 60024 FR-67401 Strasbourg, France. gilles.kauffenstein@gmail.com.

Patrick Ohlmann (P)

Pôle d'Activité Médico-Chirurgicale Cardio-Vasculaire, Nouvel Hôpital Civil, Centre Hospitalier Universitaire, Fédération de Médecine Translationnelle de Strasbourg, Strasbourg, BP 426-67091 France.

Valérie B Schini-Kerth (VB)

INSERM UMR1260 Regenerative NanoMedicine, Fédération de Médecine Translationnelle de Strasbourg, Université de Strasbourg, Faculté de Pharmacie, BP 60024 FR-67401 Strasbourg, France.

Laurence Jesel (L)

INSERM UMR1260 Regenerative NanoMedicine, Fédération de Médecine Translationnelle de Strasbourg, Université de Strasbourg, Faculté de Pharmacie, BP 60024 FR-67401 Strasbourg, France.
Pôle d'Activité Médico-Chirurgicale Cardio-Vasculaire, Nouvel Hôpital Civil, Centre Hospitalier Universitaire, Fédération de Médecine Translationnelle de Strasbourg, Strasbourg, BP 426-67091 France.

Olivier Morel (O)

INSERM UMR1260 Regenerative NanoMedicine, Fédération de Médecine Translationnelle de Strasbourg, Université de Strasbourg, Faculté de Pharmacie, BP 60024 FR-67401 Strasbourg, France. olivier.morel@chru-strasbourg.fr.
Pôle d'Activité Médico-Chirurgicale Cardio-Vasculaire, Nouvel Hôpital Civil, Centre Hospitalier Universitaire, Fédération de Médecine Translationnelle de Strasbourg, Strasbourg, BP 426-67091 France. olivier.morel@chru-strasbourg.fr.

Classifications MeSH